Trial · NCT01151579
Effect of Nebulized Bronchodilators on Heart Rate
NCT01151579, Phase 4, Completed, Fahim Khorfan, MD; results first posted 2015-10-23
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effect of Nebulized Bronchodilators on Heart Rate. Trials, record NCT01151579. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01151579
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of Nebulized Bronchodilators on Heart Rate
- NCT number
- NCT01151579
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 89 participants, actual
- Lead sponsor
- Fahim Khorfan, MD
- Conditions
- COPD, Sepsis, Shock
- Interventions
- Levalbuterol, Albuterol
- First posted
- 2010-06-28
- Last updated
- 2015-10-23
- Results first posted
- 2015-10-23
- Limitations and caveats
Potential limitations are its single-center site and that the design may not have adequately eliminated all carryover effects from the levalbuterol. However, the number of side effects without carryover would be even lower than we observed.
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Heart Rate in Beats Per Minute | Five days | Average difference in Heart rate between pre and post breathing treatments |
| Secondary | Arrhythmias | 15 minutes after each treatment for average of 3 to 5 days | Any new arrhythmia documented in the medical record that occurred between breathing treatments. |
| Secondary | Total Number of Participants With Arrhythmias | Five days | Documented new arrhythmia occurring during study. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Heart Rate in Beats Per Minute | Five days | Average change in heart rate from baseline to final breathing treatment. | bpm | MEAN |
| SECONDARY | Arrhythmias | 15 minutes after each treatment for average of 3 to 5 days | The percentage of arrhythmias among the number of breathing treatments. | percent | NUMBER |
| SECONDARY | Total Number of Participants With Arrhythmias | Five days | Number of patients for whom arrhythmias occurred within 5 days after treatment initiation. | participants | NUMBER |
Source ClinicalTrials.gov
Results by group6
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Heart Rate in Beats Per Minute | Nebulized Albuterol 2.5mg | -0.16 | Standard Deviation 5.1 | bpm | |
| Heart Rate in Beats Per Minute | Levalbuterol 1.25 | 1.40 | Standard Deviation 5.4 | bpm | |
| Arrhythmias | Nebulized Albuterol 2.5mg | 0.33 | percent | ||
| Arrhythmias | Levalbuterol 1.25 | 1.3 | percent | ||
| Total Number of Participants With Arrhythmias | Nebulized Albuterol 2.5mg | 2 | participants | ||
| Total Number of Participants With Arrhythmias | Levalbuterol 1.25 | 3 | participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Nebulized Albuterol 2.5mg | 58 | |
| Overall Study | STARTED | Levalbuterol 1.25 | 31 | |
| Overall Study | COMPLETED | Nebulized Albuterol 2.5mg | 46 | |
| Overall Study | COMPLETED | Levalbuterol 1.25 | 24 | |
| Overall Study | NOT COMPLETED | Nebulized Albuterol 2.5mg | 12 | |
| Overall Study | NOT COMPLETED | Levalbuterol 1.25 | 7 |
Source ClinicalTrials.gov
Adverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Ventricular tachycardia | Cardiac disorders | Nebulized Albuterol 2.5mg | 2 | 58 | 2 |
| serious | Ventricular tachycardia | Cardiac disorders | Levalbuterol 1.25 | 3 | 31 | 3 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Nebulized Albuterol 2.5mg | ||
| Total, all-cause mortality | Levalbuterol 1.25 | ||
| Total, other adverse events | Nebulized Albuterol 2.5mg | 0 | 58 |
| Total, other adverse events | Levalbuterol 1.25 | 0 | 31 |
| Total, serious adverse events | Nebulized Albuterol 2.5mg | 2 | 58 |
| Total, serious adverse events | Levalbuterol 1.25 | 3 | 31 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 21960699 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Nebulized Albuterol 2.5mg vs Levalbuterol 1.25: Total Number of Participants With Arrhythmias | Trial comparisons |
| Nebulized Albuterol 2.5mg vs Levalbuterol 1.25: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01151579
GET https://conductscience.org/api/trials/v1/NCT01151579/registered